Alnylam Pharmaceuticals
ALNY
452 hedge funds and large institutions have $20.9B invested in Alnylam Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 162 increasing their positions, 165 reducing their positions, and 59 closing their positions.
2% less repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 165
1% less ownership
Funds ownership: 95.24% → 94.23% (-1%)
5% less funds holding
Funds holding: 476 → 452 (-24)
7% less capital invested
Capital invested by funds: $22.5B → $20.9B (-$1.68B)
15% less call options, than puts
Call options by funds: $172M | Put options by funds: $203M
27% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 59
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$93.5M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$81.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$69.5M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$41.4M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$30.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$231M |
| 2 |
Morgan Stanley
New York
|
-$128M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$43.7M |
| 4 |
Two Sigma Investments
New York
|
-$42.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$33.1M |
ALNY Hedge Fund Activity: Q3 2023 in Review
452 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2023, worth a combined $20.9B — down 7.4% from $22.5B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of ALNY and 43 opened new positions — a net loss of 16 holders — while 165 trimmed existing stakes and 162 added.
The largest buyer was Norges Bank, adding an estimated $93.5M. The largest seller was Fidelity Investments, cutting an estimated $231M.
- 452 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2023, down from 476 in Q2 2023.
- Funds reported $20.9B of Alnylam Pharmaceuticals stock for Q3 2023, down 7.4% quarter-over-quarter.
- 43 funds opened new Alnylam Pharmaceuticals positions in Q3 2023 and 59 closed out, a net change of -16 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2023 was Norges Bank, an estimated $93.5M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2023 was Fidelity Investments, an estimated $231M sold.
Based on aggregated 13F filings for Q3 2023.